Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered”In the company’s words, NCT06501586 on ClinicalTrials.gov
- Tested for
- Hypertension,Essential
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.”In the company’s words, NCT06501586 on ClinicalTrials.gov
Other drugs for Hypertension,Essential
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- Valsartan Oral SolutionShandong New Time Pharmaceutical Co., LTD · Phase 3
- AD-227AAddpharma Inc. · Phase 3
- AD-227BAddpharma Inc. · Phase 3
- QR12000Wuhan Createrna Science and Technology Co., Ltd · Phase 3
- Sacubitril∙ValsartanChong Kun Dang Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 7 Apr 2025 | Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026